3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms;
Non-GAAP Adjusted Net Income Down 12.7% YoY in RMB terms;
Net Income Up 4.1% YoY to $32.9 Million
Board of Directors Approves $100 Million Share Repurchase Program
BEIJING, Nov. 2, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2018.
Third Quarter 2018 Financial Highlights
"In line with our previously revised forecast for the full year 2018, our results in the third quarter reflected the impact of ongoing regulatory changes and intensified competition in China's plasma industry," said China Biologic Chairman David Hui Li. "We were, however, pleased to make significant progress in both attracting industry talent and strengthening our sales and marketing efforts. I am confident that we now have the right corporate direction, product strategy and management team in place to build a world class biopharmaceutical and biotechnology company, with a leading position in key therapeutic areas. Our future growth will benefit from China's rapidly growing health care market, as well as our exploration of opportunities for expansion in international markets."
"In the third quarter, we were excited to announce the appointment of Dr. Bing Li as our new CEO. With Dr. Li's deep industry experience and leadership, China Biologic is well positioned to further improve our governance and management systems as we upgrade our internal capabilities and explore strategic acquisitions to enhance both our portfolio of high growth products and our sales and marketing capabilities."
Dr. Bing Li, CEO of China Biologic, said, "In the third quarter of 2018, we made progress on strengthening China Biologic's commercial capabilities through the recruitment of several industry veterans to our sales and marketing team. As an industry leader, China Biologic will continue to educate Chinese doctors about the benefits of IVIG, PCC and other coagulation products in treating chronic patients across a wide range of clinical indications, as we see strong growth potential in this underdeveloped industry segment. We have also taken further steps to improve the Company's corporate governance and improve important aspects of operation, with new hires in leadership roles expected to be on board by the end of the year. As part of our core strategy, we are actively pursuing suitable M&A targets that will position China Biologic for long-term growth."
"Looking into the fourth quarter and beyond, our new sales and marketing talent will be dedicated to expanding sales coverage and deepening penetration at the hospital level. These efforts will help decrease the inventory position of our products, which is currently at higher than normal levels, both internally and with our distributors."
Share Repurchase Program
The company today announced that its Board of Directors has authorized a share repurchase program under which China Biologic may repurchase up to US$100 million worth of shares over the next 6 months.
The Company's repurchases may be made from time to time on the open market at prevailing market prices, in negotiated transactions off the market, in block trades or through other legally permissible means. The timing and extent of any purchases will depend upon market conditions, the trading price of its shares and other factors, and are subject to the restrictions relating to volume, price and timing under applicable law.
Third Quarter 2018 Financial Performance
Total sales in the third quarter of 2018 increased by 21.9% in RMB terms, or 19.6% in USD terms, to $119.1 million from $99.6 million in the same quarter of 2017. The increase in total sales was partly attributable to an $11.5 million contribution from TianXinFu, which accounted for approximately 9.7% of total sales for the quarter. Excluding TianXinFu, total sales in the third quarter of 2018 increased by 10.2% in RMB terms, attributable to the sales increases in placenta polypeptide products, human albumin products, coagulation factor products, and certain immunoglobulin products, which was partly offset by the decrease in the sales of IVIG products. For plasma products, total sales in the third quarter of 2018 increased by 6.7% in RMB terms, or 4.6% in USD terms, to $88.4 million from $84.5 million in the same quarter of 2017.
During the third quarter of 2018, human albumin and IVIG products remained the Company's two largest sales contributors. Revenue from human albumin increased by 20.6% in RMB terms, or 18.3% in USD terms, from $32.8 million in the third quarter of 2017 to $38.8 million in the third quarter of 2018. Revenue from IVIG products decreased by 19.6% in RMB terms, or 21.2% in USD terms, from $30.7 million in the third quarter of 2017 to $24.2 million in the third quarter of 2018. As a percentage of total sales, sales from human albumin and IVIG products were 32.6% and 20.3%, respectively, in the third quarter of 2018. Excluding the contribution from TianXinFu, human albumin and IVIG products represented 36.1% and 22.5% of total sales, respectively, compared to 33.0% and 30.9%, respectively, in the third quarter of 2017. The large decrease of IVIG sales' percentage mainly reflected the combined effects of decreased sales volume and sales prices year over year.
The sales volume of human albumin products increased by 28.8% for the third quarter of 2018 compared to the same quarter of 2017, primarily due to increased sales volumes in the distributor and pharmacy channels, which was partly offset by decreased prescription volumes at various hospitals due to the ongoing healthcare regulatory changes in China. The sales volume of IVIG products decreased by 17.6% for the third quarter of 2018 compared to the same quarter of 2017, mainly reflecting decreased prescription volumes at various hospitals with the same effect of policy headwinds to human albumin.
The average prices for human albumin and IVIG products decreased by 6.4% and 2.5%, respectively, in RMB terms in the third quarter of 2018 compared to the same quarter of 2017 because of greater sales volume in the distributor channel and lower prices to certain distributors reflecting intensified market competition for major plasma products. In USD terms, the average price for human albumin and IVIG products decreased by 8.2% and 4.3% year over year, respectively.
Revenue from specialty immunoglobulin products increased by 21.8% in RMB terms, or 19.5% in USD terms, in the third quarter of 2018 compared to the same quarter of 2017, reaching 14.9% of total sales. This increase was mainly due to higher sales volumes of human tetanus immunoglobulin products and human rabies immunoglobulin products.
Revenue from coagulation factor products, including human coagulation factor VIII, human prothrombin complex concentrate, and the newly launched human fibrinogen products, increased by 27.1% in RMB terms, or 24.6% in USD terms, in the third quarter of 2018 compared to the same quarter of 2017, representing 6.4% of total sales. The growth mainly came from the launch of our human fibrinogen products in the beginning of 2018.
Revenue from placenta polypeptide products increased by 30.2% in RMB terms, or 27.7% in USD terms, in the third quarter of 2018 compared to the same quarter of 2017, reaching 16.1% of total sales, which was supported by higher unit selling prices in connection with the wider implementation of the two-invoice policy. However, the sales volume of placenta polypeptide products continued to decline as a result of their inclusion in regional supplemental drug lists, which put pressure on their prescription volume.
Cost of sales increased by 17.0% to $37.9 million in the third quarter of 2018 compared to the same quarter of 2017. As a percentage of total sales, cost of sales decreased to 31.8% from 32.6% in the same quarter of 2017. The decrease in cost of sales as a percentage of total sales mainly reflected the higher gross margin of TianXinFu. Excluding TianXinFu, cost of sales increased to 33.4% of total sales, mainly because of lower sales prices for its human albumin and IVIG products, which was partly offset by a higher sales price for the Company's placenta polypeptide product.
Gross profit increased by 21.0% to $81.2 million in the third quarter of 2018 from $67.1 million in the same quarter of 2017. Gross margin was 68.2% and 67.4% in the third quarters of 2018 and 2017, respectively.
Total operating expenses in the third quarter of 2018 was $52.5 million compared to $29.1 million in the same quarter of 2017. As a percentage of total sales, total operating expenses increased to 44.1% in the third quarter of 2018 from 29.2% in the same quarter of 2017. Excluding TianXinFu, total operating expenses increased by $18.3 million, or 62.9%, to $47.4 million in the third quarter of 2018. This increase mainly consisted of an increase of $13.1 million in selling expenses and an increase of $4.1 million in general and administrative expenses, excluding TianXinFu.
Selling expenses in the third quarter of 2018 was $27.4 million compared to $10.3 million in the same quarter of 2017. Approximately half of the increase was related to the sales of placenta polypeptide products with the remainder related to the sales of plasma products and TianXinFu's sales of its dura mater products. For placenta polypeptide products and certain hyper-immune products, because certain previous multi-layer distributor channels were disqualified due to the two-invoice regulation, the Company implemented new sales strategies including using an internal sales force and engaging third party contract service organizations to promote its products. For other plasma products, in order to solidify its competitiveness within distributor channel customers, the Company incurred additional promotion and marketing costs. TianXinFu's selling expenses included a $2.0 million amortization expense for the intangible asset of customer relationships associated with the Company's acquisition of TianXinFu. Excluding this intangible asset amortization expense, selling expenses accounted for 21.4% of total sales in the third quarter of 2018 compared to 10.4% in the same quarter of 2017.
General and administrative expenses in the third quarter of 2018 was $22.2 million compared to $17.4 million in the same quarter of 2017. As a percentage of total sales, general and administrative expenses were 18.6% and 17.5% in the third quarter of 2018 and the same quarter of 2017, respectively. The increase in general and administrative expenses largely resulted from increased legal fees mainly in relation to the lawsuit filed against the Company in the Cayman Islands by Mr. David (Xiaoying) Gao, the former Chairman and CEO of the Company whose employment with the Company had previously been terminated for cause; Shandong Taibang's increased depreciation expenses and property tax for its new facility; and an increase of one-time provisions in connection with certain fixed assets among certain non-operating collection stations, which was partly offset by a decrease in share-based compensation expenses for the third quarter of 2018 compared to same quarter of 2017.
Research and development expenses in the third quarter of 2018 was $2.9 million compared to $1.4 million in the same quarter of 2017. As a percentage of total sales, research and development expenses increased to 2.4% in the third quarter of 2018 from 1.4% in the same quarter of 2017.
Income from operations for the third quarter of 2018 decreased by 23.1% in RMB terms, or 24.5% in USD terms, to $28.7 million from $38.0 million in the same quarter of 2017. Operating margin decreased to 24.1% in the third quarter of 2018 from 38.2% in the same quarter of 2017. Excluding TianXinFu, income from operations for the third quarter of 2018 decreased by 34.8% in RMB terms, or 36.1% in USD terms, to $24.3 million, and operating margin decreased to 22.6%.
Income tax benefit was $3.6 million for the third quarter of 2018 compared to an income tax expense of $5.7 million in the same quarter of 2017, mainly due to a $7.5 million reversal of U.S. corporate income tax. For the year ended December 31, 2017, we recorded a one-time income tax charge of $40.3 million, which represented the management's estimation of the amount of U.S. corporate income tax based on the deemed repatriation to the United States of the Company's accumulated earnings mandated by the new U.S. income tax law that went into effect on December 22, 2017 (the "U.S. Tax Reform"). Based on several new regulations and rules issued by the U.S. Department of the Treasury in August 2018, the management reassessed the amount and reversed $7.5 million in the third quarter of 2018. Excluding the tax reversal impact, the effective income tax rate was 11.5% and 13.8% for the third quarters of 2018 and 2017, respectively.
Net income attributable to the Company increased by 6.3% in RMB terms, or 4.1% in USD terms, to $32.9 million in the third quarter of 2018 from $31.6 million in the same quarter of 2017. Net margin decreased to 27.6% in the third quarter of 2018 from 31.7% in the same quarter of 2017. Diluted net earnings per share decreased to $0.94 in the third quarter of 2018 compared to $1.11 in the same quarter of 2017. Excluding TianXinFu, net income attributable to the Company decreased by 5.7% in RMB terms, or 7.6% in USD terms, in the third quarter of 2018 compared to the same quarter of 2017, and net margin decreased to 27.1% in the third quarter of 2018 from 31.7% in the same quarter of 2017.
Non-GAAP adjusted income from operations decreased by 15.6% in RMB terms, or 17.4% in USD terms, to $38.5 million in the third quarter of 2018 from $46.6 million in the same quarter of 2017. Excluding TianXinFu, non-GAAP adjusted income from operations decreased by 29.5% in RMB terms, or 30.9% in USD terms, in the third quarter of 2018 compared to the same quarter of 2017.
Non-GAAP adjusted net income attributable to the Company decreased by 12.7% in RMB terms and 14.5% in USD terms, to $33.7 million in the third quarter of 2018 from $39.4 million in the same quarter of 2017. Non-GAAP net margin decreased to 28.3% in the third quarter of 2018 from 39.6% in the same quarter of 2017. Non-GAAP adjusted net income per diluted share decreased to $0.96 in the third quarter of 2018 from $1.38 in the same quarter of 2017. Excluding TianXinFu, non-GAAP adjusted net income attributable to the Company decreased by 25.8% in RMB terms, or 27.4% in USD terms, in the third quarter of 2018 compared to the same quarter of 2017.
Non-GAAP adjusted income from operations for the third quarter of 2018 excludes $7.8 million in non-cash employee share-based compensation expenses, and $2.0 million in amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu.
Non-GAAP adjusted net income and diluted earnings per share for the third quarter of 2018 exclude $6.9 million in non-cash employee share-based compensation expenses, $1.4 million in amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu, and an income tax benefit of $7.5 million related to U.S. Tax Reform.
First Nine Months 2018 Financial Performance
Total sales in the first nine months of 2018 increased by 20.4% in RMB terms, or 25.5% in USD terms, to $351.9 million from $280.3 million in the same period of 2017. This includes a $35.9 million contribution from TianXinFu, which accounts for approximately 10.2% of total sales for the first nine months of 2018. Excluding TianXinFu, total sales in the first nine months of 2018 increased by 8.1% in RMB terms as a result of increases in the sales of placenta polypeptide products, human albumin products, and certain immunoglobulin products, which was partly offset by decreases in the sales of IVIG products. For plasma products, total sales in the first nine months of 2018 increased by 2.8% in RMB terms, or 7.3% in USD terms, to $263.7 million from $245.8 million in the same period of 2017. As a percentage of total sales, sales from human albumin products and IVIG products accounted for 31.5% and 23.9%, respectively, for the first nine months of 2018. Excluding the contribution from TianXinFu, human albumin and IVIG products were 35.0% and 26.6% of total sales, respectively.
Cost of sales increased by 15.2% to $109.2 million in the first nine months of 2018 compared to $94.8 million in the same period of 2017. As a percentage of total sales, cost of sales decreased to 31.0% from 33.8% in the same period of 2017. The decrease in cost of sales as a percentage of total sales mainly reflected the higher gross margin of TianXinFu. Excluding TianXinFu, cost of sales decreased to 33.1% of total sales, mainly due to the higher sales price of the Company's placenta polypeptide product, which was partly offset by lower sales prices for its human albumin and IVIG products.
Gross profit increased by 30.8% to $242.7 million in the first nine months of 2018 from $185.5 million in the same period of 2017. Gross margin was 69.0% and 66.2% in the first nine months of 2018 and 2017, respectively.
Total operating expenses in the first nine months of 2018 was $139.3 million compared to $69.3 million in the same period of 2017. As a percentage of total sales, total operating expenses increased to 39.6% in the first nine months of 2018 from 24.7% in the same period of 2017. Excluding TianXinFu, total operating expenses increased by $54.6 million, or 78.8%, to $123.9 million in the first nine months of 2018. This increase mainly consisted of an increase of $42.9 million in selling expenses and an increase of $11.3 million in general and administrative expenses.
Income from operations for the first nine months of 2018 decreased by 15.1% in RMB terms, or 11.0% in USD terms, to $103.5 million from $116.3 million in the same period of 2017. Excluding TianXinFu, income from operations for the first nine months of 2018 decreased by 28.1% in RMB terms, or 24.5% in USD terms, in the first nine months of 2018 compared to the same period of 2017.
Income tax expense in the first nine months of 2018 decreased to $9.8 million from $19.5 million in the same period of 2017. The decrease was mainly because of a reversal of $7.5 million U.S. corporate income tax based on the deemed repatriation to the United States of the Company's accumulated earnings mandated by the U.S. Tax Reform, according to new regulations and rules issued by the U.S. Department of the Treasury in August 2018. Excluding the tax reversal impact, the effective income tax rate was 14.6% and 15.7% for the first nine months of 2018 and 2017, respectively.
Net income attributable to the Company decreased by 3.5% in RMB terms, and increased slightly by 0.5% in USD terms, to $93.1 million in the first nine months of 2018 from $92.6 million in the same period of 2017. Net margin decreased to 26.5% in the first nine months of 2018 from 33.0% in the same period of 2017. Diluted earnings per share for the first nine months of 2018 decreased to $2.66 from $3.25 for the same period of 2017. Excluding TianXinFu, net income attributable to the Company decreased by 17.1% in RMB terms, or 13.6% in USD terms, in the first nine months of 2018 compared to the same period of 2017, and net margin decreased to 25.3%.
Non-GAAP adjusted income from operations decreased by 6.7% in RMB terms, or 2.3% in USD terms, to $137.8 million in the first nine months of 2018 from $141.0 million in the same period of 2017. Excluding TianXinFu, non-GAAP adjusted income from operations decreased by 21.9% in RMB terms, or 18.2% in USD terms in the first nine months of 2018 compared to the same period of 2017.
Non-GAAP adjusted net income attributable to the Company decreased by 4.5% in RMB terms, or remained stable in USD terms, at $115.3 million in the first nine months of 2018 compared with the same period of 2017. Non-GAAP adjusted net income per diluted share decreased to $3.29 in the first nine months of 2018 from $4.05 in the same period of 2017. Excluding TianXinFu, non-GAAP adjusted net income attributable to the Company decreased by 19.1% in RMB terms, or 15.4% in USD terms, in the first nine months of 2018 compared to the same period of 2017.
Non-GAAP adjusted income from operations for the first nine months of 2018 excludes $27.7 million in non-cash employee share-based compensation expenses, $6.6 million in amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu.
Non-GAAP adjusted net income and diluted earnings per share for the first nine months of 2018 exclude $25.1 million in non-cash employee share-based compensation expenses, $4.5 million in amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu, and an income tax benefit of $7.5 million related to U.S. Tax Reform.
As of September 30, 2018, the Company had $186.4 million in cash on hand and demand deposits, $595.6 million in time deposits, and $171.2 million in financial instruments.
Net cash provided by operating activities for the first nine months of 2018 was $71.0 million, including a $14.2 million contribution from TianXinFu, compared to $72.6 million for the same period of 2017. Excluding TianXinFu, the $15.8 million decrease in net cash provided by operating activities was a combined result of: 1) the negative impact from a decrease in net income, an increase in accounts receivable, an increase in prepayments and deferred expenses, and decreases in income tax payable; and 2) the positive impact from an increase of other payables and accrued liabilities, and a slowdown of increase in inventory compared to the first nine months of 2017.
Excluding TianXinFu, accounts receivable increased by $47.7 million during the first nine months of 2018 compared to $37.8 million in the same period of 2017. The accounts receivable turnover days for plasma products increased to 94 days during the first nine months of 2018 from 55 days in the same period of 2017, reflecting longer credit terms to hospitals as a result of the nationwide healthcare regulation changes and intensified competition in the distributor channel.
Excluding TianXinFu, inventories increased by $32.4 million in the first nine months of 2018. This is slightly lower than a $34.0 million inventory increase in the same period of 2017, when Shandong Taibang stockpiled raw material and WIP during the planned temporary production suspension.
Excluding TianXinFu, other payables and accrued liabilities increased by $28.6 million in the first nine months of 2018 compared to an increase of $9.9 million in the first nine months of 2017. The increase mainly reflected more marketing activities carried out by third party contract service organizations that the Company engaged to promote its placenta polypeptide and certain plasma products in compliance with the two-invoice policy.
Net cash used in investing activities for the first nine months of 2018 was $686.2 million compared to $28.4 million for the same period of 2017. Net cash used in investing activities in the first nine months of 2018 mainly consisted of a $1,680.5 million payment for the purchase of time deposits and financial instruments and a $26.9 million payment for the acquisition of property, plant, and equipment, intangible assets, and land use rights. This was partly offset by $97.7 million in cash received upon acquisition of TianXinFu and the maturity of $923.4 million in time deposits and financial instruments. In the same period of 2017, the Company paid $28.5 million for the acquisition of property, plant, and equipment and land use rights for Shandong Taibang and Guizhou Taibang.
Net cash provided by financing activities for the first nine months of 2018 was $581.3 million compared to net cash used in financing activities of $18.4 million for the same period of 2017. Net cash provided by financing activities in the first nine months of 2018 represented $590.3 million proceeds from the issuance and sale of an aggregate of 5,850,000 ordinary shares of the Company to certain investors in late third quarter of 2018, and $1.2 million from stock options exercised, partially offset by a dividend of $10.1 million paid by Shandong Taibang to its noncontrolling interest shareholders. Net cash used in financing activities in the first nine months of 2017 mainly consisted of $18.8 million dividends paid by Shandong Taibang to its noncontrolling interest shareholders.
Financial Outlook
The Company reiterates its previously revised full year 2018 forecast. The Company expects non-GAAP adjusted income from operations to increase by 0% to 2% in RMB terms and non-GAAP adjusted net income to decrease by 2% to 4% in RMB terms over full year 2017 financial results. Excluding TianXinFu, full year 2018 non-GAAP adjusted income from operations is expected to decrease by 16% to 18% in RMB terms and non-GAAP adjusted net income to decrease by 19% to 21% in RMB terms over full year 2017 financial results.
This guidance does not factor in any potential foreign currency translation impact. Having previously adopted an exchange rate of approximately RMB6.76 = $1.00 based on weighted average quarterly exchange rates in 2017 in translating 2017 financial results, the Company expects that the non-GAAP adjusted income from operations and non-GAAP adjusted net income in USD terms in 2018 could be affected by the foreign currency translation impact.
This guidance excludes potential acquisitions, and necessarily assumes no significant adverse product price changes during 2018. This forecast reflects the Company's current and preliminary views, which are subject to change.
Conference Call
The Company will host a conference call at 7:30 am Eastern Time on November 2, 2018, which is 7:30 pm Beijing Time on November 2, 2018, to discuss its third quarter 2018 results and answer questions from investors. Listeners may access the call by dialing:
US: |
1 888 346 8982 |
International: |
1 412 902 4272 |
Hong Kong: |
852 301 84992 |
China: |
4001 201203 |
A telephone replay will be available one hour after the conclusion of the conference through November 9, 2018. The dial-in details are:
US: |
1 877 344 7529 |
International: |
1 412 317 0088 |
Passcode: |
10125875 |
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com.
About China Biologic Products Holdings, Inc.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.
Non-GAAP Disclosure
This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options and restricted shares granted to employees and directors under the Company's 2008 Equity Incentive Plan, amortization of acquired intangible assets and land use rights, and an income tax benefit related to U.S. Tax Reform. To supplement the Company's unaudited consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this release. The Company's management believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. A reconciliation of the adjustments to GAAP results appears in the table accompanying this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.
In addition, as the Company evaluates certain key items of its financial results on a local currency basis (i.e., in RMB) in addition to the reporting currency (i.e., in USD), this news release contains local currency information that eliminates the impact of fluctuations in foreign currency exchange rates. The Company believes that, given its operations primarily based in China, providing local currency information on such key items enhances the understanding of its financial results and evaluation of performance in comparison to prior periods. Changes in local currency percentages are calculated by comparing financial results denominated in RMB from period to period.
Safe Harbor Statement
This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products Holdings, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "intend," "believe," "expect," "are expected to," "will," or similar expressions, and involve known and unknown risks and uncertainties. Among other things, the Company's plans regarding the construction and operation of plasma collection stations, the commercial launch of pipeline products and the integration with TianXinFu, as well as the management's quotations and forecast of the Company's financial performance in this news release contain forward-looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.
Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, without limitation, quality of purchased source plasma, potential delay or failure to complete construction of new collection facilities, potential inability to pass government inspection and certification process for existing and new facilities, potential inability to achieve the designed collection capacities at the new collection facilities, potential inability to achieve the expected operating and financial performance, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contact:
China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
The Foote Group
Mr. Philip Lisio
Phone: +86-135-0116-6560
Email: phil@thefootegroup.com
(Financial statements on the following pages)
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES |
|||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME |
|||||||
For the Three Months Ended |
For the Nine Months Ended |
||||||
September 30, 2018 |
September 30, 2017 |
September 30, 2018 |
September 30, 2017 |
||||
USD |
USD |
USD |
USD |
||||
Sales: |
119,106,754 |
99,561,251 |
351,948,937 |
280,292,260 |
|||
Human Albumin |
38,820,347 |
32,814,153 |
110,750,427 |
102,047,466 |
|||
Human Immunoglobulin for Intravenous Injection |
24,231,787 |
30,724,570 |
84,128,156 |
92,141,052 |
|||
Other Immunoglobulin products |
17,754,624 |
14,855,226 |
46,180,028 |
35,858,831 |
|||
Placenta Polypeptide |
19,203,232 |
15,037,482 |
52,311,027 |
34,510,237 |
|||
Artificial Dura Mater |
9,976,001 |
- |
32,735,840 |
- |
|||
Others |
9,120,763 |
6,129,820 |
25,843,459 |
15,734,674 |
|||
Cost of sales |
37,874,952 |
32,424,522 |
109,205,180 |
94,750,267 |
|||
Gross profit |
81,231,802 |
67,136,729 |
242,743,757 |
185,541,993 |
|||
Operating expenses |
|||||||
Selling expenses |
27,441,971 |
10,311,284 |
72,489,297 |
17,696,435 |
|||
General and administrative expenses |
22,195,036 |
17,369,133 |
60,165,137 |
46,890,375 |
|||
Research and development expenses |
2,898,115 |
1,409,226 |
6,560,990 |
4,691,260 |
|||
Income from operations |
28,696,680 |
38,047,086 |
103,528,333 |
116,263,923 |
|||
Other income (expenses) |
|||||||
Equity in income of an equity method investee |
521,213 |
1,114,784 |
2,019,767 |
2,998,886 |
|||
Interest expense |
(64,563) |
(129,787) |
(200,236) |
(478,655) |
|||
Interest income |
3,705,168 |
1,781,576 |
9,946,304 |
5,022,469 |
|||
Fair value changes of financial instruments |
1,181,400 |
- |
3,807,865 |
- |
|||
Total other income, net |
5,343,218 |
2,766,573 |
15,573,700 |
7,542,700 |
|||
Income before income tax expense |
34,039,898 |
40,813,659 |
119,102,033 |
123,806,623 |
|||
Income tax expense |
(3,614,695) |
5,650,621 |
9,836,443 |
19,468,594 |
|||
Net income |
37,654,593 |
35,163,038 |
109,265,590 |
104,338,029 |
|||
Less: Net income attributable to noncontrolling interest |
4,733,252 |
3,597,923 |
16,116,303 |
11,750,581 |
|||
Net income attributable to China Biologic Products Holdings, Inc. |
32,921,341 |
31,565,115 |
93,149,287 |
92,587,448 |
|||
Earnings per share of ordinary share: |
|||||||
Basic |
0.94 |
1.11 |
2.67 |
3.28 |
|||
Diluted |
0.94 |
1.11 |
2.66 |
3.25 |
|||
Weighted average shares used in computation: |
|||||||
Basic |
33,973,834 |
27,430,784 |
33,937,057 |
27,277,823 |
|||
Diluted |
34,077,426 |
27,657,806 |
34,078,243 |
27,535,624 |
|||
Net income |
37,654,593 |
35,163,038 |
109,265,590 |
104,338,029 |
|||
Other comprehensive income: |
|||||||
Foreign currency translation adjustment, net of nil income taxes |
(52,258,441) |
11,305,814 |
(64,060,220) |
24,719,100 |
|||
Comprehensive income |
(14,603,848) |
46,468,852 |
45,205,370 |
129,057,129 |
|||
Less: Comprehensive income attributable to noncontrolling interest |
(1,294,335) |
4,836,621 |
8,578,116 |
14,347,082 |
|||
Comprehensive income attributable to China Biologic Products Holdings, Inc. |
(13,309,513) |
41,632,231 |
36,627,254 |
114,710,047 |
|||
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES |
||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS |
||||
September 30, 2018 |
December 31, 2017 |
|||
USD |
USD |
|||
ASSETS |
||||
Current Assets |
||||
Cash and cash equivalents |
186,415,243 |
219,336,848 |
||
Time deposits |
595,605,010 |
22,895,200 |
||
Financial instruments |
171,181,058 |
- |
||
Accounts receivable, net of allowance for doubtful accounts |
117,768,996 |
77,267,275 |
||
Loan receivable - current |
- |
45,912,000 |
||
Inventories |
234,106,644 |
209,570,835 |
||
Prepayments and other current assets, net of allowance for doubtful |
29,513,540 |
18,139,453 |
||
Total Current Assets |
1,334,590,491 |
593,121,611 |
||
Property, plant and equipment, net |
177,737,929 |
166,812,749 |
||
Intangible assets, net |
54,341,019 |
536,338 |
||
Land use rights, net |
27,400,023 |
24,853,163 |
||
Equity method investment |
15,041,973 |
14,903,908 |
||
Loan receivable - non-current |
40,991,531 |
- |
||
Goodwill |
312,878,547 |
- |
||
Other non-current assets |
11,386,252 |
8,829,648 |
||
Total Assets |
1,974,367,765 |
809,057,417 |
||
LIABILITIES AND SHAREHOLDERS' EQUITY |
||||
Current Liabilities |
||||
Accounts payable |
7,152,500 |
7,548,909 |
||
Income tax payable |
11,848,817 |
14,258,544 |
||
Other payables and accrued expenses |
105,296,794 |
75,827,864 |
||
Total Current Liabilities |
124,298,111 |
97,635,317 |
||
Deferred income |
2,939,018 |
3,476,877 |
||
Non-current income tax payable |
26,899,038 |
37,067,138 |
||
Other liabilities |
12,946,520 |
6,553,088 |
||
Total Liabilities |
167,082,687 |
144,732,420 |
||
Shareholders' Equity |
||||
Ordinary share: |
||||
par value $0.0001; |
||||
100,000,000 shares authorized; |
||||
41,616,020 and 29,866,545 shares issued at September 30, 2018 and |
||||
39,361,316 and 27,611,841 shares outstanding at September 30, 2018 and |
4,162 |
2,987 |
||
Additional paid-in capital |
1,194,258,324 |
140,230,395 |
||
Treasury share: 2,254,704 shares at September 30, 2018 and December31, |
(56,425,094) |
(56,425,094) |
||
Retained earnings |
599,575,723 |
506,426,436 |
||
Accumulated other comprehensive income |
(48,564,729) |
7,957,304 |
||
Total equity attributable to China Biologic Products Holdings, Inc. |
1,688,848,386 |
598,192,028 |
||
Noncontrolling interest |
118,436,692 |
66,132,969 |
||
Total Shareholders' Equity |
1,807,285,078 |
664,324,997 |
||
Commitments and contingencies |
- |
- |
||
Total Liabilities and Shareholders' Equity |
1,974,367,765 |
809,057,417 |
||
Note: "Ordinary share" when used with respect to a date before July 21, 2017 refers to the common stock of our predecessor, China Biologic |
||||
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES |
||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||
For the Nine Months Ended |
||||
September 30, |
September 30, |
|||
2018 |
2017 |
|||
USD |
USD |
|||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||
Net income |
109,265,590 |
104,338,029 |
||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||
Depreciation |
10,809,288 |
9,154,528 |
||
Amortization |
7,391,494 |
948,945 |
||
Loss on sale of property, plant and equipment |
119,658 |
136,496 |
||
Fair value changes of financial instruments |
(3,807,868) |
- |
||
Allowance for doubtful accounts - accounts receivable, net |
1,125,569 |
23,783 |
||
Write-down of obsolete inventories |
428,741 |
- |
||
Impairment for non-current assets |
777,946 |
- |
||
Deferred tax benefit |
(6,119,956) |
(1,770,326) |
||
Share-based compensation |
27,694,079 |
24,715,534 |
||
Equity in income of an equity method investee |
(2,019,767) |
(2,998,886) |
||
Change in operating assets and liabilities: |
||||
Accounts receivable |
(47,682,569) |
(37,784,029) |
||
Inventories |
(34,667,723) |
(34,030,811) |
||
Prepayments and other current assets |
(11,583,687) |
(1,840,311) |
||
Accounts payable |
2,611,758 |
(88,625) |
||
Income tax payable |
(2,717,011) |
2,690,364 |
||
Other payables and accrued expenses |
30,565,526 |
9,432,501 |
||
Deferred income |
(384,334) |
(367,750) |
||
Non-current income tax payable |
(10,769,674) |
- |
||
Net cash provided by operating activities |
71,037,060 |
72,559,442 |
||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||
Cash acquired from acquisition of Tianxinfu |
97,702,278 |
- |
||
Purchase of time deposit |
(1,116,354,557) |
- |
||
Maturity of time deposit |
536,098,566 |
- |
||
Purchase of financial instruments |
(564,125,165) |
- |
||
Maturity of financial instruments |
387,319,807 |
- |
||
Payment for property, plant and equipment |
(26,193,022) |
(27,755,853) |
||
Payment for intangible assets and land use rights |
(700,458) |
(733,513) |
||
Proceeds from sale of property, plant and equipment |
26,785 |
46,264 |
||
Net cash used in investing activities |
(686,225,766) |
(28,443,102) |
||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||
Proceeds from stock option exercised |
1,180,854 |
836,897 |
||
Proceeds from short-term bank loans |
- |
23,009,280 |
||
Repayment of short-term bank loan |
- |
(23,412,060) |
||
Proceeds from the issuance and sale of ordinary shares |
590,265,000 |
- |
||
Dividend paid by subsidiaries to noncontrolling interest shareholders |
(10,145,395) |
(18,789,152) |
||
Net cash provided by (used in ) financing activities |
581,300,459 |
(18,355,035) |
||
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH |
966,642 |
6,918,216 |
||
NET (DECREASE)INCREASE IN CASH AND CASH EQUIVALENTS |
(32,921,605) |
32,679,521 |
||
Cash and cash equivalents at beginning of period |
219,336,848 |
183,765,533 |
||
Cash and cash equivalents at end of period |
186,415,243 |
216,445,054 |
||
Supplemental cash flow information |
||||
Cash paid for income taxes |
30,691,960 |
18,767,908 |
||
Noncash investing and financing activities: |
||||
Acquisition of property, plant and equipment included in payables |
4,781,628 |
3,374,860 |
||
Issuance of ordinary shares in connection with the Tianxinfu acquisition |
434,889,170 |
- |
||
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES |
|||||
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES |
|||||
For the Three Months Ended |
|||||
September 30, |
September 30, |
||||
2018 |
2017 |
||||
USD |
USD |
||||
Income from Operations |
28,696,680 |
38,047,086 |
|||
Non-cash employee share-based compensation |
7,847,253 |
8,514,344 |
|||
Amortization of acquired intangible assets and land use rights |
1,985,958 |
- |
|||
Adjusted Income from Operations - Non GAAP |
38,529,891 |
46,561,430 |
|||
Net Income Attributable to the Company |
32,921,341 |
31,565,115 |
|||
Non-cash employee share-based compensation |
6,949,127 |
7,798,705 |
|||
Amortization of acquired intangible assets and land use rights |
1,350,452 |
- |
|||
Income tax benefit related to U.S. Tax Reform |
(7,519,674) |
- |
|||
Adjusted Net Income Attributable to the Company - Non GAAP |
33,701,246 |
39,363,820 |
|||
Diluted EPS - Non GAAP |
0.96 |
1.38 |
|||
Weighted average number of shares used in computation of Non GAAP diluted EPS |
34,077,426 |
27,657,806 |
|||
For the Nine Months Ended |
|||||
September 30, |
September 30, |
||||
2018 |
2017 |
||||
USD |
USD |
||||
Income from Operations |
103,528,333 |
116,263,923 |
|||
Non-cash employee share-based compensation |
27,694,079 |
24,715,534 |
|||
Amortization of acquired intangible assets and land use rights |
6,615,610 |
- |
|||
Adjusted Income from Operations - Non GAAP |
137,838,022 |
140,979,457 |
|||
Net Income Attributable to the Company |
93,149,287 |
92,587,448 |
|||
Non-cash employee share-based compensation |
25,125,971 |
22,712,507 |
|||
Amortization of acquired intangible assets and land use rights |
4,498,615 |
- |
|||
Income tax benefit related to U.S. Tax Reform |
(7,519,674) |
- |
|||
Adjusted Net Income Attributable to the Company - Non GAAP |
115,254,199 |
115,299,955 |
|||
Diluted EPS - Non GAAP |
3.29 |
4.05 |
|||
Weighted average number of shares used in computation of Non GAAP diluted EPS |
34,078,243 |
27,535,624 |
|||
View original content:http://www.prnewswire.com/news-releases/china-biologic-reports-financial-results-for-the-third-quarter-of-2018-300742192.html